Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH

Daniel M. Moreira, Lauren E. Howard, Katharine N. Sourbeer, Hiruni S. Amarasekara, Lydia C. Chow, Dillon C. Cockrell, Connor L. Pratson, Brian T. Hanyok, William J. Aronson, Christopher J. Kane, Martha K. Terris, Christopher Amling, Matthew R. Cooperberg, Stephen J. Freedland

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Micro-Abstract We investigated the predictors of time from metastatic castration-resistant prostate cancer (mCRPC) to all-cause mortality among patients treated at Veteran Affairs hospitals. We found that age, more remote year of mCRPC, greater number of bone metastasis, higher prostate-specific antigen levels, and shorter prostate-specific antigen doubling time at mCRPC diagnosis were associated with shorter overall survival. A nomogram was generated yielding good concordance and calibration.

Original languageEnglish (US)
Pages (from-to)60-66.e2
JournalClinical Genitourinary Cancer
Volume15
Issue number1
DOIs
StatePublished - Feb 1 2017

    Fingerprint

Keywords

  • Disease-free survival
  • Mortality
  • Prostate cancer
  • Prostate-specific antigen
  • Prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Moreira, D. M., Howard, L. E., Sourbeer, K. N., Amarasekara, H. S., Chow, L. C., Cockrell, D. C., Pratson, C. L., Hanyok, B. T., Aronson, W. J., Kane, C. J., Terris, M. K., Amling, C., Cooperberg, M. R., & Freedland, S. J. (2017). Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clinical Genitourinary Cancer, 15(1), 60-66.e2. https://doi.org/10.1016/j.clgc.2016.08.018